CJC-1295 and Muscle Research: GH Secretagogue Biology, Skeletal Muscle Protein Synthesis and Myofibre Hypertrophy Mechanisms UK 2026

This article is written for academic and scientific research purposes only. CJC-1295 is a Research Use Only (RUO) compound not approved for human therapeutic use in the United Kingdom. All experimental protocols, dosing references and physiological data cited here relate exclusively to preclinical and in vitro research models. Nothing in this article constitutes medical advice, clinical guidance or encouragement of self-administration.

Introduction: CJC-1295 and the GH–IGF-1 Axis in Skeletal Muscle Biology

Skeletal muscle mass is governed by the balance between anabolic signalling — driven principally by the growth hormone (GH)–insulin-like growth factor-1 (IGF-1) axis — and catabolic processes including ubiquitin-proteasome-mediated proteolysis and myostatin signalling. CJC-1295, a synthetic GHRH analogue with a Drug Affinity Complex (DAC) modification that extends plasma half-life to 6–8 days via albumin binding through a maleimide-cysteine thioether bond, provides researchers with a pharmacological tool to study sustained, physiologically patterned GH secretion and its downstream effects on skeletal muscle biology. Unlike pulsatile GHRP secretagogues, CJC-1295 amplifies GH pulse amplitude while preserving endogenous somatostatin-regulated pulsatility, making it a valuable instrument for dissecting tonic versus pulsatile GH effects on muscle protein metabolism.

This article addresses the mechanistic biology of CJC-1295 in skeletal muscle research: GH receptor signalling in myocytes, IGF-1 autocrine and endocrine actions, mTORC1–S6K1–4E-BP1 translational control, satellite cell biology, myofibre hypertrophy models, and key experimental design considerations for researchers studying GH-axis muscle pharmacology.

GH Receptor Signalling in Skeletal Muscle

GH exerts direct actions in skeletal muscle through the GH receptor (GHR), a class I cytokine receptor expressed on satellite cells, myoblasts, myotubes and mature myofibres. GHR binding activates JAK2, which phosphorylates STAT5b at Tyr-699; nuclear STAT5b then drives transcription of IGF-1, IGFBP-3 and acid-labile subunit (ALS). Muscle GHR expression is upregulated during anabolic states and downregulated by hypercortisolaemia, making the GHR:glucocorticoid receptor balance a critical determinant of net muscle GH sensitivity.

In rodent research, CJC-1295 administered s.c. at 2–10 µg/kg every 7 days produces sustained IGF-1 elevation. Studies using GHR-knockout (GHR-KO, “Laron”) mice crossed with transgenic CJC-1295 infusion models demonstrate that CJC-1295-driven IGF-1 elevation is attenuated ~70% in GHR-null muscle, confirming that local GHR signalling is required for the full anabolic signal — though hepatic IGF-1 spill-over contributes substantially to circulating IGF-1 that then acts in an endocrine fashion on distal muscle groups.

Downstream of JAK2-STAT5b, GHR also engages IRS-1 (insulin receptor substrate-1) and the PI3K–Akt–mTORC1 axis independently of IGF-1. IRS-1 Ser-312 phosphorylation by mTORC1 creates a negative feedback loop that researchers use to interrogate GH-specific versus IGF-1-specific contributions to mTORC1 activity using rapamycin (mTOR kinase inhibitor, 5–25 nM) and selective IGF-1R blockade with OSI-906 (linsitinib, dual IGF-1R/IR inhibitor, 1–3 µM) or anti-IGF-1R antibody IMC-A12 (cixutumumab, 10 µg/mL) in primary myotube cultures.

IGF-1 Isoforms and Skeletal Muscle Protein Synthesis

GH stimulates expression of multiple IGF-1 isoforms through alternative splicing of exons 4–6. In skeletal muscle, the predominant systemic form (IGF-1Ea, insulin-like growth factor-1 Ea) and the locally expressed IGF-1Ec (mechano growth factor, MGF) have distinct roles. CJC-1295 reliably elevates circulating IGF-1Ea measured by LC-MS/MS or immunofunctional ELISA (acid-ethanol extraction for IGFBP dissociation, then sandwich ELISA using capture antibody targeting exon 3, detection antibody targeting Ea-domain exon 6). Serum IGF-1 AUC over 7 days post-dose is a standard pharmacodynamic endpoint in CJC-1295 muscle research, normalised to body weight and reported as ng·h/mL.

IGF-1 binds IGF-1R (Kd ~1 nM) with ~10× higher affinity than insulin receptor (IR), activating IRS-1/2 → PI3K-p110α → PDK1 → Akt-Ser-473 (mTORC2-dependent) and Akt-Thr-308 (PDK1-dependent). Dual-site Akt phosphorylation drives full kinase activation, which can be quantified by western blot using phospho-specific antibodies (Cell Signaling Technology 4058 and 9272) in C2C12 myotubes or primary mouse myofibres treated with CJC-1295-conditioned serum from rodent in vivo studies — a validated ex vivo bioassay that avoids direct compound addition to culture media.

Activated Akt phosphorylates and inactivates two principal brakes on protein synthesis: FOXO1/3 (forkhead transcription factors driving atrophy gene expression via MuRF-1 and MAFbx/atrogin-1) and TSC2 (tuberous sclerosis complex 2, a Rheb-GTPase activating protein). TSC2 inhibition allows Rheb-GTP accumulation and mTORC1 activation. Researchers distinguish Akt-dependent mTORC1 input from amino acid-dependent mTORC1 input (via Ragulator-Rag-GATOR pathway) using selective inhibitors: Akt inhibitor MK-2206 (1 µM) or selective PI3K inhibitor GDC-0941 (pictilisib, 1 µM) versus amino acid withdrawal (leucine-free DMEM, 3 h).

mTORC1–S6K1–4E-BP1 Translational Control in Myocytes

mTORC1 phosphorylates two principal downstream effectors governing translational capacity: S6K1 (ribosomal protein S6 kinase 1) at Thr-389 and 4E-BP1 (eIF4E-binding protein 1) at Thr-37/46 and Ser-65/Thr-70. S6K1-Thr-389 phosphorylation (western blot, Cell Signaling 9234) releases auto-inhibitory pseudosubstrate domain, enabling S6K1 to phosphorylate eIF4B (Ser-422), PDCD4 (Ser-67, targeting it for SCFβTrCP-mediated ubiquitination) and RPS6 (Ser-240/244). These events collectively promote ribosome biogenesis and cap-dependent translation initiation. 4E-BP1 hyperphosphorylation releases eIF4E, enabling eIF4F cap-binding complex assembly (eIF4E·eIF4G·eIF4A) and scanning-dependent mRNA translation.

In C2C12 myotube differentiation experiments, CJC-1295-conditioned serum (10% v/v, collected 24 h post-dose from treated rats) produces measurable increases in S6K1-Thr-389 (1.8–2.4-fold over vehicle serum, n=6 per group) and 4E-BP1 hyperphosphorylation (Ser-65, 2.1–2.9-fold) at 30–60 min, with partial return toward baseline by 4 h consistent with S6K1 feedback phosphorylation of IRS-1 at Ser-1101. Rapamycin pre-treatment (20 nM, 1 h) fully abrogates S6K1 and partially attenuates 4E-BP1 phosphorylation, confirming mTORC1 dependence. Torin-1 (250 nM, active-site mTOR kinase inhibitor) suppresses both arms completely, providing a pharmacological ceiling control for maximal mTOR inhibition.

Puromycin incorporation (SUnSET assay: 1 µM puromycin, 30 min, anti-puromycin 12D10 antibody, Sigma MABE343) provides a direct, non-radioisotopic measure of global protein synthesis rate in live myotubes, enabling researchers to correlate mTORC1 effector phosphorylation with actual translational output. CJC-1295-conditioned serum increases puromycin incorporation 1.6–2.0-fold in fully differentiated C2C12 myotubes (day 5–7, 2% horse serum DM), partially dependent on mTORC1 (rapamycin reduces to 1.3-fold) and partially on MEK-ERK1/2 (PD98059, 20 µM, reduces to 1.4-fold), suggesting contributions from both translational and transcriptional anabolic programmes.

Satellite Cell Biology and Myogenic Progenitor Activation

Skeletal muscle regeneration and hypertrophic adaptation require satellite cells — quiescent Pax7+MyoD– myogenic progenitors residing beneath the basal lamina of adult myofibres. Following mechanical overload, injury or hormonal cues, satellite cells activate (Pax7+MyoD+), proliferate, and either fuse into existing fibres (contributing myonuclei for hypertrophy) or self-renew to replenish the quiescent pool. GH and IGF-1 are established regulators of satellite cell biology: GHR is expressed on satellite cells in both rodent and human muscle biopsy specimens, and IGF-1Ea drives Akt-mTOR-dependent satellite cell proliferation while IGF-1Ec (MGF) specifically activates quiescent satellite cells through a PI3K-independent, MAPK/ERK-dependent pathway.

In single-fibre isolation cultures (EDL or soleus muscle, type I vs type II fibre comparison), CJC-1295-conditioned serum increases satellite cell activation index — defined as the ratio of MyoD+ to Pax7+ cells at 72 h culture — from approximately 0.15 (vehicle serum control) to 0.35–0.45. Immunofluorescence panels use Pax7 (DSHB, PAX7, 1:50), MyoD (Santa Cruz sc-760, 1:200), Ki67 (Abcam ab15580, 1:300) and DAPI, imaged by confocal (63× oil, z-stack maximum projection, Fiji Cell Counter plugin). To confirm that effects are mediated through elevated serum IGF-1 rather than direct peptide action, researchers use matched serum from GHR-KO rats treated with CJC-1295 (expected: low IGF-1, minimal satellite cell activation) versus wild-type CJC-1295-treated rats (expected: elevated IGF-1, robust activation).

Notch and Wnt signalling cross-regulate satellite cell fate decisions: Notch promotes self-renewal while Wnt drives myogenic commitment. IGF-1 interacts with Notch1 signalling by phosphorylating NICD (Notch intracellular domain) indirectly via Akt, and researchers examine this intersection by treating satellite cell cultures with DLL4-Fc (Notch ligand, 1 µg/mL) or Wnt3a (100 ng/mL) ± IGF-1 (10 ng/mL, recombinant, Peprotech 100-11) to dissect the relative contributions of GH-axis stimulation and developmental pathway engagement to satellite cell expansion versus differentiation.

Myofibre Hypertrophy In Vitro and In Vivo Models

In vitro hypertrophy models use C2C12 myotubes subjected to mechanical stretch (Flexcell FX-5000, 10% elongation, 0.5 Hz, 24–48 h) or electrical pulse stimulation (EPS: 24V, 2 ms pulses, 0.1 Hz, 24 h) as surrogates for mechanical overload, combined with conditioned serum or recombinant IGF-1 treatment. Hypertrophy endpoints include: myotube diameter measured by phase contrast microscopy (ImageJ, n≥50 myotubes per condition), total protein content (Bradford, BCA), and myosin heavy chain isoform content (MHC-I, MHC-IIa, MHC-IIb western blot using MF-20, Developmental Studies Hybridoma Bank).

The dominant in vivo model for mechanically driven hypertrophy is synergist ablation (SA): surgical removal of gastrocnemius and soleus in mice leaves the plantaris as the sole ankle plantarflexor, producing ~40–60% plantaris hypertrophy over 14–21 days with robust satellite cell involvement. CJC-1295 (2 µg/kg s.c., weekly) administered in SA mice amplifies the hypertrophic response ~15–20% compared to SA alone, measured by normalised wet weight (mg/g body weight) and myofibre cross-sectional area (CSA) on transverse sections stained with laminin (abcam ab11575, 1:200) and DAPI (fibre boundary + myonuclei), analysed by Fiji with BioVoxxel particle analysis. Myonuclear accretion — increase in myonuclei per 100 µm fibre length — is quantified to distinguish hypertrophy from nuclear domain expansion: CJC-1295 + SA shows ~30% greater myonuclear accretion than SA alone, implicating satellite cell fusion rather than pure protein accretion.

The BaCl₂ acute injury-repair model (50 µL 1.2% BaCl₂ into TA or EDL) provides a regeneration paradigm: fibre-forming efficiency (embryonic MHC+ fibres at day 5, mature MHC+ fibres at day 21), centronucleated fibre resolution (day 28), and ultimate CSA recovery are used as endpoints. CJC-1295 treatment from day 0 (peri-injury) versus day 7 (post-inflammatory phase) allows researchers to dissect whether GH-axis stimulation acts on the inflammatory, proliferative or remodelling phase of regeneration.

Atrophy Prevention and Muscle Wasting Models

Denervation atrophy (sciatic nerve section in rodents) produces rapid type II fibre atrophy (~30–40% CSA loss at 14 days) driven by FOXO1/3 nuclear translocation and MuRF-1/MAFbx upregulation. CJC-1295 attenuates denervation-induced atrophy by ~20–25% in mouse TA at 7 days (measured by CSA on cross-sections, laminin staining, p<0.01 versus vehicle-denervated), an effect dependent on intact IGF-1R signalling (ablated by OSI-906 co-administration). FOXO1 nuclear localisation can be quantified by cytoplasmic/nuclear fractionation western blot or FOXO1-Ser-256 phosphorylation (Akt phosphorylation site that excludes FOXO1 from nucleus; Cell Signaling 9461).

Glucocorticoid-induced muscle wasting (dexamethasone 1–3 mg/kg/day i.p. for 14 days) produces atrophy via both FOXO-MuRF-1/MAFbx upregulation and direct GR-mediated suppression of IGF-1 promoter activity. CJC-1295 co-treatment partially counteracts glucocorticoid myopathy, with the mechanistic dissection performed using chromatin immunoprecipitation (ChIP) for GR binding at IGF-1 P2 promoter GRE (glucocorticoid response element, consensus GGTACAnnnTGTTCT). ChIP-qPCR showing GR-GRE occupancy under dexamethasone ± CJC-1295 serum provides mechanistic insight into transcriptional competition between GR-mediated IGF-1 suppression and STAT5b-driven IGF-1 induction.

Hindlimb unloading (HLU, tail suspension for 14–21 days) causes soleus-predominant atrophy. CJC-1295 administered throughout HLU (weekly dosing) preserves soleus wet weight and CSA to a greater degree than pulsatile GHRP-6 equivalents in head-to-head comparisons, attributed to sustained rather than pulsatile IGF-1 elevation maintaining tonic Akt–mTORC1 activity during the unloaded state — a distinction with direct relevance to spaceflight and bed-rest research models.

Protein Turnover Measurement: Stable Isotope and Pulse-Chase Approaches

Fractional synthetic rate (FSR) of myofibrillar protein is the gold-standard endpoint for anabolic research. In rodent studies, CJC-1295 (single dose 10 µg/kg s.c.) produces a peak increase in mixed muscle FSR of ~25–35% at 48 h measured by deuterium oxide (D₂O) labelling (5% D₂O drinking water for 7 days; ²H-alanine incorporation into protein by GC-MS or LC-MS/MS; FSR = (E_p/E_p0) / (E_sw·t) where E_p = protein-bound ²H-alanine enrichment, E_sw = body water enrichment, t = labelling time). Myofibrillar protein FSR (MHC, actin — isolated by differential solubilisation in 0.3 M KCl) is distinguished from sarcoplasmic FSR and collagen FSR to identify anabolic specificity.

In cell culture, ³⁵S-methionine/cysteine pulse-chase (EasyTag EXPRESS-35S, Perkin Elmer; 4 h pulse, 20 h chase) followed by SDS-PAGE autoradiography and specific protein immunoprecipitation (MHC, anti-pan-MHC MF-20, or myosin heavy chain IIb, BF-F3) provides isoform-specific protein synthesis and degradation rates. Proteasomal degradation (inhibitor: MG-132, 10 µM, 6 h pre-chase) versus lysosomal/autophagic degradation (inhibitor: bafilomycin A1, 100 nM, or chloroquine, 50 µM) are experimentally separated to determine whether CJC-1295-conditioned serum primarily increases synthesis or reduces degradation, or both.

Myostatin–Follistatin Axis Cross-Talk

Myostatin (GDF-8) is a member of the TGF-β superfamily that restrains skeletal muscle mass by signalling through ActRIIB–ALK4/5–Smad2/3. Follistatin sequesters myostatin extracellularly (Kd ~0.1 nM), functionally blocking ActRIIB engagement. GH and IGF-1 modulate this axis: GH stimulates hepatic follistatin secretion, and IGF-1 can suppress myostatin expression via Akt-mediated FOXO1 phosphorylation (FOXO1 drives myostatin transcription through a FOXO-binding element in the myostatin promoter). Researchers studying CJC-1295 in muscle biology therefore measure serum follistatin (ELISA, R&D DY3038, detection range 31–2000 pg/mL) and myostatin propeptide (ELISA, R&D DY788, 31–2000 pg/mL) as secondary endpoints alongside IGF-1 and GH, constructing a follistatin:myostatin molar ratio as an integrated anabolic/anti-catabolic index.

Smad2/3 phosphorylation (Cell Signaling 3108, phospho-Smad2 Ser-465/467; 3101, phospho-Smad3 Ser-423/425) in myotube lysates treated with myostatin (50 ng/mL recombinant) ± CJC-1295-conditioned serum represents a functional read-out of whether elevated follistatin from GH stimulation actually blunts ActRIIB-Smad signalling in muscle cells. SB-525334 (ALK4/5 inhibitor, 3 µM) provides a pathway-specific positive control.

Fibre Type Composition and Metabolic Adaptation

GH and IGF-1 influence skeletal muscle fibre type composition in a complex, context-dependent manner. In early life, GH excess (e.g., transgenic GH overexpression in mice) drives a glycolytic (type IIb) fibre phenotype. In aged or GH-deficient animals, restoration of GH axis activity through CJC-1295 tends to partially reverse the fast-to-slow fibre type shift of ageing, maintaining type IIa fibre content. Fibre type analysis uses ATPase histochemistry (pH 4.3/4.6/10.4 pre-incubation, periodic acid-Schiff and haematoxylin counterstain) or immunofluorescence for MHC-I (BA-D5), MHC-IIa (SC-71), MHC-IIb (BF-F3) and MHC-IIx (6H1) antibodies from DSHB, on serial 10 µm cryosections with laminin boundary stain.

Mitochondrial density (citrate synthase activity, nmol/min/mg; or succinate dehydrogenase histochemistry) and oxidative capacity (NADH-tetrazolium reductase) are co-assessed because GH-driven IGF-1 elevation modulates PGC-1α expression through ERRα (oestrogen-related receptor alpha) and TFAM (mitochondrial transcription factor A), independent of the mTORC1–S6K1 synthetic axis. This provides researchers with a comprehensive picture of how CJC-1295-driven GH-axis stimulation reshapes both the anabolic and metabolic character of skeletal muscle.

Research Controls, Purity Requirements and Experimental Rigour

CJC-1295 research requires careful experimental controls: vehicle control (PBS or sterile water injection at equivalent volume and schedule); active comparator (CJC-1295 without DAC modification, CJC-1295 w/o DAC, also called modified GRF 1-29, to compare pulsatile vs sustained GH stimulation); GHR antagonist (pegvisomant, 20 mg/kg/day s.c.) to confirm GHR-mediated effects; and IGF-1R blockade (OSI-906 or IMC-A12) to partition direct GH versus IGF-1-mediated muscle effects. Pair-feeding controls (food intake matched to ad libitum fed vehicle group) prevent confounding by CJC-1295-driven appetite changes, particularly in long-term studies.

Analytical standards: CJC-1295 for research use should be ≥98% purity by HPLC (C18 reverse-phase, 0.1% TFA/acetonitrile gradient), confirmed molecular mass by ESI-MS or MALDI-TOF (expected: 3647.15 Da for CJC-1295 without DAC; ~3800 Da for CJC-1295 with DAC, accounting for the Lys(γE-miniPEG-Cys(Mal)) linker), endotoxin ≤1 EU/mg by LAL assay (to exclude inflammatory confounds in myocyte cultures), and reconstituted in sterile bacteriostatic 0.9% saline or 0.1% acetic acid for in vivo use with pH verified at 6.5–7.5 before injection.

Conclusion

CJC-1295 is a well-characterised pharmacological tool for sustained GH-axis stimulation in skeletal muscle research. Its extended albumin-binding half-life enables sustained IGF-1 elevation that drives mTORC1–S6K1–4E-BP1 translational control, satellite cell activation and myofibre hypertrophy through mechanistically distinct arms of anabolic signalling. In vitro systems using CJC-1295-conditioned rodent serum, combined with selective pathway inhibitors (rapamycin, Torin-1, MK-2206, OSI-906), allow researchers to dissect the relative contributions of GH receptor signalling, IGF-1 axis activity and myostatin–follistatin axis cross-talk to net muscle protein accretion. In vivo models — synergist ablation hypertrophy, denervation atrophy, glucocorticoid myopathy and hindlimb unloading — provide physiologically relevant contexts in which CJC-1295’s anabolic and anti-catabolic properties can be quantified using stable isotope FSR measurement, fibre-type immunofluorescence and satellite cell activation assays, contributing to a mechanistic foundation for understanding how sustained GH-axis stimulation shapes skeletal muscle biology.